Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine

PURPOSE: Predictive biomarkers for capecitabine benefit in triple-negative breast cancer (TNBC) have been recently proposed using samples from phase III clinical trials, including non-basal phenotype and biomarkers related to angiogenesis, stroma, and capecitabine activation genes. We aimed to valid...

Descripción completa

Detalles Bibliográficos
Autores principales: Asleh, Karama, Lluch, Ana, Goytain, Angela, Barrios, Carlos, Wang, Xue Q., Torrecillas, Laura, Gao, Dongxia, Ruiz-Borrego, Manuel, Leung, Samuel, Bines, José, Guerrero-Zotano, Ángel, García-Sáenz, Jose Ángel, Cejalvo, Juan Miguel, Herranz, Jesus, Torres, Roberto, de la Haba-Rodriguez, Juan, Ayala, Francisco, Gómez, Henry, Rojo, Federico, Nielsen, Torsten O., Martin, Miguel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Precision Medicine and Imaging
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9873250/
https://www.ncbi.nlm.nih.gov/pubmed/36346687
http://dx.doi.org/10.1158/1078-0432.CCR-22-2191

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9873250/
https://www.ncbi.nlm.nih.gov/pubmed/36346687
http://dx.doi.org/10.1158/1078-0432.CCR-22-2191

Ejemplares similares